Saving lives starts in the laboratory
Donate today to help provide Burnet’s labs with critical equipment.
Donate today to help provide Burnet's labs with critical equipment.
Donate today to help provide Burnet’s labs with critical equipment.
Donate today to help provide Burnet's labs with critical equipment.
28 April 2020
In one of the first COVID-19 clinical vaccine trials, US-based clinical-stage biotechnology company Novavax (NASDAQ: NVAX) has selected Australian speciality laboratory 360biolabs, to conduct sample analysis for the clinical trial of its SARS-CoV-2 recombinant spike protein nanoparticle vaccine, NVX-CoV2373.
Due to the nature and sensitivities of certain assays used in this clinical trial, a specialist biosecurity facility is required. With its highly experienced scientists working in state of the art Biosafety Level 2 (BSL-2) and 3 (BSL-3) laboratories, 360biolabs has the ideal resources and environment to conduct these crucial studies.
As Australia’s only ISO accredited, clinical services organisation, currently working with SARS-CoV-2, 360biolabs have received global requests for antiviral testing and clinical trial support. 360biolabs’ wealth of knowledge in the respiratory virus antiviral discovery and clinical space, ensures the team will delivery high quality, robust and reliable data.
360biolabs is Australia’s most comprehensive speciality laboratory services organisation for therapeutic, vaccine and diagnostics development. We develop and conduct pharmacokinetic (PK) and pharmacodynamic (PD) assays across a wide variety of therapeutic areas and provide extensive support services to ensure the success of preclinical studies and clinical trials.
We are passionate about using cutting-edge thinking and technology to support the development of therapeutics, vaccines and diagnostics.
360biolabs has cutting-edge laboratory facilities at Burnet Institute, perfectly situated to benefit from the unique advantages of conducting studies in Australia.
Visit 360biolabs.com for more information.
We offer world-leading capabilities to test and characterise antivirals, biological agents, vaccines and diagnostics. Our team has experience with a broad range of viruses and we possess an extensive curated library including clinical isolates.
Highly specialised immunoassay service supporting the development of vaccines and immunotherapies.
ICH / FDA /EMA compliant packages ensuring a defined pathway to IND Data and formal reports in accordance with the FDA’s “Guidance for Industry” Industry standard reporting formats and customisation to clients’ requirements.
Our experienced team provides expert assistance for the support of clinical trials.
Assay suite includes:
Other services include:
360biolabs is located at Burnet Institute, 85 Commercial Rd, Melbourne.
For any general enquiries relating to this facility, please contact:
Deputy Director (Partnerships), Burnet Institute; Chief Scientific Officer, Burnet Diagnostics Initiative
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2021 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
